A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G

被引:186
作者
Carosella, Edgardo D. [1 ,2 ]
Ploussard, Guillaume [3 ]
LeMaoult, Joel [1 ,2 ]
Desgrandchamps, Francois [1 ,2 ,3 ]
机构
[1] Hop St Louis, CEA, Inst Emerging Dis & Innovat Therapies iMETI, Res Div Hematol & Immunol SRHI, F-75475 Paris 10, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, Inst Univ Hematol, St Louis Hosp,UMR E 5, Paris, France
[3] Hop St Louis, Dept Urol, F-75475 Paris 10, France
关键词
Cancer immunotherapy; Monoclonal antibodies; Checkpoint; CTLA-4; PD-1; HLA-G; RESISTANT PROSTATE-CANCER; RENAL-CELL CARCINOMA; COMBINATION IMMUNOTHERAPY; UROTHELIAL CARCINOMA; ANTI-PD-L1; ANTIBODY; TUMOR VASCULATURE; CLINICAL ACTIVITY; B7-H1; EXPRESSION; PLUS IPILIMUMAB; POOR SURVIVAL;
D O I
10.1016/j.eururo.2015.02.032
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Overexpression of immune checkpoint molecules affects tumor-specific T-cell immunity in the cancer microenvironment, and can reshape tumor progression and metastasis. Antibodies targeting checkpoints could restore antitumor immunity by blocking the inhibitory receptor-ligand interaction. Objective: To analyze data and current trends in immune checkpoint targeting therapy for urologic cancers. Evidence acquisition: Systematic literature search for clinical trials in the PubMed and Cochrane databases up to August 2014 according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Endpoints included oncologic results, tumor response rates, safety, and tolerability. Evidence synthesis: Anti-CTLA-4 monotherapy has demonstrated biochemical responses in prostate cancer. One phase 3 trial assessing ipilimumab efficacy in castration-resistant disease was negative overall. Nevertheless, ipilimumab may significantly improve overall survival compared with placebo in subgroups of patients with favorable prognostic features. In renal cancer, phase 1 trials showed interesting stabilization or long-lasting objective response rates approaching 50% using anti-PD-1/PD-L1 drugs in heavily pretreated metastatic patients. In bladder cancer, one phase 2 trial indicated a good safety profile for ipilimumab as a neoadjuvant drug before radical cystectomy. Overall, immune-related effects such as colitis and dermatitis were common and well tolerated. Conclusions: Our systematic review shows that antibodies blocking immune checkpoints offer interesting and long-lasting response rates in heavily pretreated patients with advanced urologic cancers. More promising results are currently provided by anti-CTLA-4 antibodies in prostate cancer and by PD-1/PD-L1 inhibitors in renal cancer. These should encourage new clinical trials of immune therapy combinations and immunotherapy monotherapy combined with conventional anticancer drugs. In bladder cancer, the use of targeted immunotherapy still remains underevaluated; however, preliminary results reported at recent conferences seem encouraging. Patient summary: Data from studies support the activity and safety of immune checkpoint inhibitors in urologic cancers, alone or in combination with conventional cancer therapies. Encouraging data in other oncologic fields could translate into interesting responses in urological cancers. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 75 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]  
[Anonymous], ANN ONCOL
[3]   Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].
Beck, Kimberly E. ;
Blansfield, Joseph A. ;
Tran, Khoi Q. ;
Feldman, Andrew L. ;
Hughes, Marybeth S. ;
Royal, Richard E. ;
Kammula, Udai S. ;
Topalian, Suzanne L. ;
Sherry, Richard M. ;
Kleiner, David ;
Quezado, Martha ;
Lowy, Israel ;
Yellin, Michael ;
Rosenberg, Steven A. ;
Yang, James C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289
[4]   Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up [J].
Bellmunt, J. ;
Orsola, A. ;
Leow, J. J. ;
Wiegel, T. ;
De Santis, M. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2014, 25 :40-48
[5]   Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer [J].
Blansfield, JA ;
Beck, KE ;
Tran, K ;
Yang, DC ;
Hughes, MS ;
Kammula, US ;
Royal, RE ;
Topalian, SL ;
Haworth, LR ;
Levy, C ;
Rosenberg, SA ;
Sherry, RM .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :593-598
[6]   T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival [J].
Boorjian, Stephen A. ;
Sheinin, Yuri ;
Crispen, Paul L. ;
Farmer, Sara A. ;
Lohse, Christine M. ;
Kuntz, Susan M. ;
Leibovich, Bradley C. ;
Kwon, Eugene D. ;
Frank, Igor .
CLINICAL CANCER RESEARCH, 2008, 14 (15) :4800-4808
[7]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[8]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[9]   A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma [J].
Brignone, Chrystelle ;
Escudier, Bernard ;
Grygar, Caroline ;
Marcu, Manon ;
Triebel, Frederic .
CLINICAL CANCER RESEARCH, 2009, 15 (19) :6225-6231
[10]  
Bukur J, 2003, CANCER RES, V63, P4107